Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.

ABSTRACT:

Context

Methodological shortcomings often compromise investigations into the effects of primary somatostatin-analog treatment on tumor size in acromegaly. There are also limited data for the long-acting lanreotide formulation.

Objective

The aim of the study was to better characterize the effects of primary lanreotide Autogel treatment on tumor size in patients with GH-secreting macroadenomas.

Design

PRIMARYS was a 48-week, multicenter, open-label, single-arm study.

Setting

The study was conducted at specialist endocrine centers.

Patients

Treatment-naïve acromegalic patients with GH-secreting macroadenomas participated in the study.

Intervention

Lanreotide Autogel 120 mg was administered sc every 28 days (without dose titration).

Outcome measure

SUBMITTER: Caron PJ 

PROVIDER: S-EPMC4009579 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature